Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks with high potential. On October 3, Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a price target of $79.00. Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported $166 million in total revenue for fiscal Q2 2025, with Crysvita® revenue of $120 million and Dojolvi® revenue of ...